Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate

Author: Benzinga Newsdesk | November 10, 2025 04:01pm
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.90) by 45.49 percent. This is a 88.46 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $17.151 million which missed the analyst consensus estimate of $21.196 million by 19.09 percent. This is a 58.84 percent decrease over sales of $41.673 million the same period last year.

Posted In: ARCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist